Recent content

Les semences de la terre - Une richesse publique ou privee?

La situation des semences

Les anciens centres de diversite des cultures disparaissent dans le tiers-monde... quelle est l'ampleur du probleme? Que fait-on? Cette situation affecte-t-elle les approvisionnements alimentaires de la planete? Qu'est-ce que cela signifie pour les nations industrialisees "pauvres en genes"?

The CGIAR’s Third External Review

The world's largest and most influential international agricultural research network, the Consultative Group on International Agricultural Research (CGIAR), is conducting its first full systemwide review in 17 years. In May, 1998 in Brayil, a prestigious review panel led by Maurice Strong will table its recommendations for the future of the network, which launched the Green Revolution.

Animal Patenting Accelerates in US

The hesitancy with which the US Patent and Trademark Office (PTO) began granting animal patents in 1988 has all but disappeared, and today the practice is accelerating dramatically (see chart). The recent trend is fueled by a backlog of patent applications, rapid advances in biotechnologies and the promise of commercial markets for transgenic animals and the therapeutic proteins they produce. Based on the US trend, the European Union can expect hundreds of backlogged animal patents to begin issuing if the European Patent Directive is adopted - as expected - by the European Parliament's Council of Ministers later this year.

Bioethics Commission Report is "Dolly in Wolf's Clothing"

Recommendations will stimulate - not deter - commercialization of human cloning

The final, 107-page report prepared by the US National Bioethics Advisory Commission on human cloning, accepted by President Clinton on 9 June, sends a clear signal to the biotech industry that it can move full speed ahead to commercialize the cloning of animals, including human beings," says Pat Mooney, Executive Director of RAFI. "The Commission seems to have sidestepped all the tough ethical issues," Mooney continues, "and has reduced the broad moral debate solely to a question of safety for mother and embryo."

Bolivian Farmers Demand Researchers Drop Patent on Andean Food Crop

Bolivia's National Association of Quinoa Producers (ANAPQUI) is asking two professors at Colorado State University to abandon their controversial patent on one of the country's most important food crops - quinoa (Chenopodium quinoa) - a crop that feeds millions throughout the Andes, including many Aymara and Quechua Indigenous People.

Volume 4, #2 The Aksum Commission

CGRFA: Guiding Global Governance - A Civil Society Report

The CGRFA held its  7th regular session in Rome from 15-23 May, 1997. the commission's 154 member countries had 2 tasks: to continue negotiations leading to a legally-binding International Undertaking covering plant genetic resources that could become an agricultural protocol to the Biodiversity Convention, and, to maintain the momentum achieved through last year's Leipzig Conference on Plant Genetic Resources. Most commission members exceeded their own expectations regarding the International Undertaking - but they fell short of the acceptable minimum on the second objectve.

Biotech Industry Sweet on African Plant Proteins

Commercial development of sweet proteins derived from African plants could be worth millions if new, natural sweeteners can bite into the (US) $2 billion low-calorie sweetener market.(1)

Research on intensely sweet proteins is not new, but recent breakthroughs may improve prospects for commercial development.

Supply-side Science for the South?

TAC's Biotech Gambit

In recent years, the CGIAR ( Consultative Group on International Agricultural Research) has come under fire for a governance structure that far more reflects the orientation of scientists in the North than it does their counterparts in the South. At the time of the CG's second review in 1981, there were slightly more South trustees in the system than North. During the nineties however, the tables have turned, and the North now dominates the roster with most of the trustees and almost all of the key management positions. Since he took over the reins as Chair of the CGIAR in 1994, the World Bank's Ismail Serageldin has fought an uphill battle with the 16 International Agricultural Research Centres (IARCS) that form the CG network in order to increase the role of the South. Many credit Serageldin with limited, but praiseworthy, success.

No Cure for Patents

Biotech Patents Distort and Discourage Innovation and Increase Costs for Dubious Drugs

It's not whether drug companies need patents to create new drugs - but whether society can survive monopoly control over medical research, according to research undertaken by RAFI (Rural Advancement Foundation International). The world's drug industry represents a health risk and cannot be entrusted with the task of medical research," Pat Mooney, executive director of RAFI insists.

Sovereignty or Hegemony? Africa and Security - Negotiating from Reality

Critical Crops; Patent Claims on Cloning

Will governments opt for a multilateral system of crop germplasm exchange or will they determine to pursue bilateral agreements between countries and companies? RAFI examines Africa's bargaining position, and concludes that bilateral negotiations over crop germplasm will benefit the North, at the expense of food security in the South.

Volume 4, #1 Guiding Global Governance

A Civil Society Perspective on Food Security, Agriculture, and Biodiversity Issues in the Multilateral Arena

RAFI's analysis of overlapping agendas for biodiversity, food security and genetic resources in the multilateral arena. The year 1996 was critical for food security, agricultural development, and biodiversity. The fights and fora include: FAO World Food Summit, the Leipzig Conference on Plant Genetic Resources, the Convention on Biological Diversity (CBD) the Consultative Group on International Agricultural Research (CGIAR). A 12 page document.

Bioserfdom: Technology, Intellectual Property and the Erosion of Farmers' Rights in the Industrialized World

Gene Licensing Agreements; Precision Farming

Two trends in industrial agriculture are contributing to the erosion of farmers' rights and lead to bioserfdom: 1) Monsanto's 1996 gene licensing agreement; 2) "Precision farming" and the role it plays in the commodification of information technology and the growing influence of the life industry in farm-level decision-making.

Colombian Indigenous People Negotiate to get Human Tissue Samples Back

A Colombian genetics institute has offered to return its collection of thousands of samples of human tissue collected in dozens of Colombian indigenous peoples' communities. Indigenous peoples' representatives, including Colombian Senator Lorenzo Muelas and the OrganizaciÛn Nacional IndÌgena de Colombia (ONIC - National Indigenous Peoples' Organisation of Colombia), are currently negotiating the formal return of control and ownership of the samples, which are housed in a Bogot· human tissue bank.

IOCD's Biotic Exploration Fund

Development Programme or Corporate Proxy?

If you have a close eye on bioprospecting, you may have heard about the particularly grandiose plans of the International Organisation for Chemical Sciences in Development's (IOCD) Biotic Exploration Fund". The Fund is a major international effort to promote bioprospecting originally proposed by Thomas Eisner, an academic who "conceived and facilitated" the Merck/InBio deal in Costa Rica. IOCD has hired a former Science and Technology Adviser to the World Bank to push the Fund, which is being aggresively promoted to many potential Northern funding agencies.

IOCD, a Belgian-chartered international NGO with a legal identity in the United States, is unabashedly fanatical about the potential for bioprospecting to protect the environment and be a "sustainable source of economic development." In fact, according to IOCD, without bioprospecting, the world's diversity may be doomed: "In comparison with the severity of the global biodiversity crisis, the amount of bioprospecting in developing countries is clearly far too small. Hence, the only appropriate response to the global crisis would be a great expansion of the scale and quality of bioprospecting throughout the developing world."

Dolly: Clone or Commodity?

RAFI Follows the Money

Before disclosing the cloning breakthrough, patent applications were filed and research papers prepared for publication. PPL Therapeutics, a small biotechnology company will be assigned the patent. After the cloning announcement, shares of PPL Therapeutics jumped 16% in one day on the London Stock Exchange.

The Human Tissue Trade

The Global Traffic and Market in Human Biomaterials

Despite the promise of medical breakthroughs, the utilization of human tissue prompts intense ethical concerns regarding ownership of human biomaterials, eugenics, discrimination and medical confidentiality. A large and growing South to North and North to North movement of human tissue is taking place in an almost total policy and regulatory vacuum.

World's Top 10 Seed Corporations

Ranked According to 1996 Seed Sales

Company Estimated 1996 seed sales (US) millions Comment

Pioneer Hi-Bred Intl. (USA) $1,721 Dupont now owns 20% share in Pioneer

Novartis (Switzerland) $991 formerly Ciba Geigy and Sandoz

Limagrain (France) $552 French cooperative; claims to be the world's largest vegetable seed company.

Advanta - joint venture of Zeneca/Van der Have (The Netherlands) $493 Zeneca and Royal VanderHave established joint venture in 1996. The name of their merged company is Advanta

Legislation in US Congress Proposes to Privatize the US Patent and Trademark Office

Just when we thought that the U.S. patent system couldn't possibly operate any more to the advantage of big business, there's a bill before the US Congress that proposes to modernize" the US Patent and Trademark Office by making it a private corporation. (1)

Privatization of the US PTO? This is not a joke. HR 400, "The 21st Century Patent System Improvement Act" is a series of six acts that propose major changes in the US patent system. Backed by powerful interests, the bill is moving quickly through Congress, and a vote is expected in the House of Representatives any day.

Páginas

Suscribirse a Recent content